- Home
- MGRM vs LRMR Comparison
MGRM vs LRMR Comparison
Compare MGRM & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- LRMR
- Stock Information
- Founded
- MGRM 2016
- LRMR N/A
- Country
- MGRM United States
- LRMR United States
- Employees
- MGRM N/A
- LRMR N/A
- Industry
- MGRM Medical/Dental Instruments
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- LRMR Health Care
- Exchange
- MGRM Nasdaq
- LRMR Nasdaq
- Market Cap
- MGRM 195.3M
- LRMR 204.9M
- IPO Year
- MGRM N/A
- LRMR N/A
- Fundamental
- Price
- MGRM $5.35
- LRMR $3.72
- Analyst Decision
- MGRM Strong Buy
- LRMR Strong Buy
- Analyst Count
- MGRM 1
- LRMR 7
- Target Price
- MGRM $5.40
- LRMR $17.86
- AVG Volume (30 Days)
- MGRM 225.3K
- LRMR 1.6M
- Earning Date
- MGRM 08-18-2025
- LRMR 08-19-2025
- Dividend Yield
- MGRM N/A
- LRMR N/A
- EPS Growth
- MGRM N/A
- LRMR N/A
- EPS
- MGRM N/A
- LRMR N/A
- Revenue
- MGRM N/A
- LRMR N/A
- Revenue This Year
- MGRM N/A
- LRMR N/A
- Revenue Next Year
- MGRM N/A
- LRMR N/A
- P/E Ratio
- MGRM N/A
- LRMR N/A
- Revenue Growth
- MGRM N/A
- LRMR N/A
- 52 Week Low
- MGRM $1.92
- LRMR $1.61
- 52 Week High
- MGRM $6.02
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- MGRM 63.65
- LRMR 57.77
- Support Level
- MGRM $5.29
- LRMR $3.42
- Resistance Level
- MGRM $5.53
- LRMR $3.97
- Average True Range (ATR)
- MGRM 0.12
- LRMR 0.34
- MACD
- MGRM -0.13
- LRMR -0.01
- Stochastic Oscillator
- MGRM 23.08
- LRMR 51.90
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.